close
A point of care center to be established in Madrid for the development of T-cell and dendr...
News

A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies

A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies

Orgenesis, a global US biotech company developing personalized therapies and closed processing systems through its Cell & Gene Therapy (CGT) Biotech Platform, announced a research and development collaboration with Hospital Infantil Universitario Niño Jesús, Madrid, Spain, through its Biomedical Research Foundation, FIB. Under this agreement, FIB Hospital Infantil Universitario Niño Jesús will utilize Orgenesis’ CGT Biotech Platform to develop, optimize and manufacture cell and gene therapies. The first collaboration under this agreement involves the clinical development and validation of T-cell and dendritic cell-based therapies. Orgenesis’ CGT Biotech Platform, which combines processing and therapeutic technologies, is designed to allow for the efficient production of high quality, affordable cell and gene-based products. Upon successful completion of the first collaboration, Orgenesis and FIB Hospital Infantil Universitario Niño Jesús then plan to pursue the development of the Hospital’s oncolytic based cell therapy technology, Celyvir. This proprietary program represents a new strategy for the treatment of solid metastatic tumors based on oncolytic virotherapy administered by mesenchymal cells obtained from bone marrow.


Vered Caplan, CEO of Orgenesis, stated, “Hospital Infantil Universitario Niño Jesús will be an amazing addition to our POCare Network. We believe that our POCare Technologies will enable the hospital to advance this new therapy for the treatment of solid metastatic tumors based on oncolytic virotherapy. Our CGT Biotech Platform enables hospitals to accelerate the clinical development of life-saving therapies and potentially bring them to market in a more time and cost-effective manner. Furthermore, we expect that this collaboration will allow us to further develop and validate our POCare Therapies, including immune-oncology therapies.”
Dr. Manuel Ramírez MD, PhD, Head of the Pediatric Advanced Therapies Unit at Hospital Infantil Universitario Niño Jesús in Madrid, commented, “We look forward to collaborating with Orgenesis in order to develop our oncolytic based cell therapy. By utilizing Orgenesis’ CGT Biotech Platform, we seek to reduce the cost of bringing our technology to market, enabling others to use it in their patients, assuring high quality standards by integrating Orgenesis’ proprietary POCare Technologies.”

May 22, 2020


COMMENTS ARE OFF THIS POST